User profiles for Nikolaos Gatselis
 | Nikolaos GatselisDpt of Medicine, National Expertise Center in Autoimmune Liver Disease, ERN, University of … Verified email at uth.gr Cited by 6732 |
[HTML][HTML] Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 …
…, O Liatsis-Douvitsas, S Symbardi, N Gatselis… - Nature medicine, 2021 - nature.com
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy
…, H Chi, S Manolakopoulos, G Mangia, N Gatselis… - Journal of …, 2016 - Elsevier
Background & Aims Risk scores for hepatocellular carcinoma (HCC) developed in Asians
offer poor-moderate predictability in Caucasian patients with chronic hepatitis B (CHB). This …
offer poor-moderate predictability in Caucasian patients with chronic hepatitis B (CHB). This …
[HTML][HTML] Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis
…, O Tsachouridou, GN Dalekos, N Gatselis… - The Lancet …, 2021 - thelancet.com
Background Anakinra might improve the prognosis of patients with moderate to severe
COVID-19 (ie, patients requiring oxygen supplementation but not yet receiving organ support). …
COVID-19 (ie, patients requiring oxygen supplementation but not yet receiving organ support). …
The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B
…, A Loglio, S Siakavellas, O Keskın, N Gatselis… - …, 2017 - Wiley Online Library
Whether there is a change of hepatocellular carcinoma (HCC) incidence in chronic hepatitis
B patients under long‐term therapy with potent nucleos(t)ide analogues is currently unclear. …
B patients under long‐term therapy with potent nucleos(t)ide analogues is currently unclear. …
An open label trial of anakinra to prevent respiratory failure in COVID-19
Background: It was studied if early suPAR-guided anakinra treatment can prevent severe
respiratory failure (SRF) of COVID-19. Methods: A total of 130 patients with suPAR ≥6 ng/ml …
respiratory failure (SRF) of COVID-19. Methods: A total of 130 patients with suPAR ≥6 ng/ml …
[HTML][HTML] Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics
Autoimmune hepatitis (AIH) is an unresolving progressive liver disease of unknown etiology
characterized by hypergammaglobulinemia, autoantibodies detection and interface hepatitis…
characterized by hypergammaglobulinemia, autoantibodies detection and interface hepatitis…
Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large …
BACKGROUND & AIMS: Standard therapy for autoimmune hepatitis (AIH) is corticosteroids
with or without azathioprine. However, 20% of patients do not respond or are intolerant to …
with or without azathioprine. However, 20% of patients do not respond or are intolerant to …
Adipokines as mediators of endothelial function and atherosclerosis
For many decades, adipose tissue was considered as an inactive body compartment that
was only used as an energy store. During the recent years, an increasing amount of data has …
was only used as an energy store. During the recent years, an increasing amount of data has …
Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir
Background & Aims The risk of hepatocellular carcinoma (HCC) in Caucasian patients with
chronic hepatitis B (CHB), treated with entecavir (ETV) or tenofovir (TDF), is unclear. We …
chronic hepatitis B (CHB), treated with entecavir (ETV) or tenofovir (TDF), is unclear. We …
Complement C3 inhibition in severe COVID-19 using compstatin AMY-101
…, I Fotiadou, N Zioga, I Mitroulis, NK Gatselis… - Science …, 2022 - science.org
Complement C3 activation contributes to COVID-19 pathology, and C3 targeting has
emerged as a promising therapeutic strategy. We provide interim data from ITHACA, the first …
emerged as a promising therapeutic strategy. We provide interim data from ITHACA, the first …